{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:30:51Z","timestamp":1786116651252,"version":"build-2736575974"},"reference-count":140,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Gallbladder cancer (GBC) is a highly malignant tumor of the biliary tract system.Although it is less common than other malignant tumors of the digestive system, its incidence and mortality rates have been on a continuous rise. With insidious early symptoms, the majority of patients are diagnosed at an advanced stage when the disease is detected. Surgical resection remains the radical treatment for gallbladder cancer yet many patients lose the opportunity for surgical intervention when seeking medical attention due to the onset of symptoms.In addition, given the high invasiveness and high recurrence rate of gallbladder cancer, systemic therapy beyond surgical treatment is particularly crucial. In recent years, precision medicine centered on immunotherapy and targeted therapy has exhibited certain therapeutic effects and improved the quality of life in patients with advanced cancer. Immunotherapy is a therapeutic modality that prevents immune evasion of tumor cells, primarily by means of immune checkpoint inhibitors such as CTLA-4 and PD- 1\/PD-L1 inhibitors, among which PD-1\/PD-L1 inhibitors are widely used in the immunotherapy of gallbladder cancer.Following the success of the global Phase III TOPAZ- 1 and KEYNOTE-966 trials, durvalumab in combination with gemcitabine and cisplatin, as well as pembrolizumab combined with gemcitabine and cisplatin, have been approved in multiple countries and recommended by authoritative guidelines as the preferred first-line systemic therapeutic regimens for advanced biliary tract cancers. A number of clinical trials conducted in recent years have initiated subgroup analyses of biliary tract cancer together with detections of biomarkers and the tumor microenvironment, providing guidance for immunotherapy of gallbladder cancer. This article elaborates on the mechanisms of immune checkpoint inhibitors, the unique tumor microenvironment and biomarkers specific to gallbladder cancer, summarizes clinical trials concerning gallbladder cancer and those incorporating gallbladder cancer subgroup analyses, interprets authoritative clinical guidelines and relevant policies, and presents the strategies and procedures adopted by our team for administering immunotherapy to patients with gallbladder cancer in routine clinical practice.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1862775","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T11:33:26Z","timestamp":1786016006000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["New progress and clinical research translation of immune checkpoint inhibitors in systemic therapy of gallbladder cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Fuhong","family":"Li","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Kunming Medical University","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Kunming Medical University","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiren","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Kunming Medical University","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Kunming Medical University","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Kunming Medical University","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiawei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Kunming Medical University","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Kunming Medical University","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/jso.20527","article-title":"Gallbladder cancer","volume":"8","author":"Roa","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.4103\/ijpm.ijpm_649_25","article-title":"Tumors and tumor-like lesions of the gall bladder-a review","volume":"68","author":"Husain","year":"2025","journal-title":"Indian J Pathol Microbiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000003225","article-title":"Burden of six major types of digestive system cancers globally and in China","volume":"137","author":"Zhou","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.154684","article-title":"miRNAs orchestration of gallbladder cancer - particular emphasis on diagnosis, progression and drug resistance","volume":"248","author":"Shahin","year":"2023","journal-title":"Pathol Res Pract"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-022-03056-7","article-title":"Non-coding RNAs as potential biomarkers of gallbladder cancer","volume":"25","author":"Lv","year":"2023","journal-title":"Clin Transl Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/s2468-1253(19)30416-9","article-title":"Early detection of pancreatic cancer","volume":"5","author":"Pereira","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2022.106234","article-title":"Current management of incidental gallbladder cancer: a review","volume":"98","author":"Feo","year":"2022","journal-title":"Int J Surg"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2021.101130","article-title":"Gallbladder disorders: a comprehensive review","volume":"67","author":"Lam","year":"2021","journal-title":"Dis Mon"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2024.07.411","article-title":"'IHPBA-APHPBA clinical practice guidelines': international Delphi consensus recommendations for gallbladder cancer","volume":"26","author":"Palepu","year":"2024","journal-title":"HPB (Oxford)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i16.2369","article-title":"Current status and progress in laparoscopic surgery for gallbladder carcinoma","volume":"29","author":"Sun","year":"2023","journal-title":"World J Gastroenterol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.5833\/jjgs.9.163","article-title":"Guideline for the diagnosis and treatment of gallbladder carcinoma (2019 edition)","volume":"58","year":"2020","journal-title":"Zhonghua Wai Ke Za Zhi"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.3390\/cancers15153993","article-title":"New Era of Immune\u2011Based Therapy in Intrahepatic Cholangiocarcinoma","volume":"15","author":"Kawamura","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.5582\/bst.2022.01267","article-title":"Treatment of biliary tract carcinoma over the last 30 years","volume":"16","author":"Midorikawa","year":"2022","journal-title":"Biosci Trends"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1500091","article-title":"Comparison of treatment models for single primary advanced gallbladder cancer","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.1944","article-title":"Adjuvant gemcitabine plus cisplatin and chemoradiation in patients with gallbladder cancer: a randomized clinical trial","volume":"10","author":"Ostwal","year":"2024","journal-title":"JAMA Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-022-10343-6","article-title":"Benefit of adjuvant radiotherapy for gallbladder cancer: a comparability-based meta-analysis","volume":"16","author":"Choi","year":"2022","journal-title":"Hepatol Int"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: ready for \"prime time\" in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J Hepatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1928636","article-title":"Targeted therapies for gallbladder cancer: an overview of agents in preclinical and clinical development","volume":"30","author":"De Lorenzo","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104830","article-title":"Global perspective on the genetic, epigenetic, and transcriptomic basis of gallbladder cancer","volume":"214","author":"Das","year":"2025","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","article-title":"Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer","volume":"40","author":"Zhang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113365","article-title":"A comprehensive review of immune checkpoint inhibitors for cancer treatment","volume":"143","author":"Arafat Hossain","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102614","article-title":"Novel targets for immune-checkpoint inhibition in cancer","volume":"120","author":"Borgeaud","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.03.006","article-title":"Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy","volume":"43","author":"Wang","year":"2025","journal-title":"Cancer Cell"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13388","article-title":"Immune checkpoint inhibitors in infectious disease","volume":"328","author":"King","year":"2024","journal-title":"Immunol Rev"},{"key":"B28","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","article-title":"Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B29","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","article-title":"Combination strategies to maximize the benefits of cancer immunotherapy","volume":"14","author":"Zhu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.3390\/biom12091303","article-title":"Co-stimulatory receptor signaling in CAR-T cells","volume":"12","author":"Honikel","year":"2022","journal-title":"Biomolecules"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.08.025","article-title":"Spatiotemporal coordination of antigen presentation and co-stimulatory signal for enhanced anti-tumor vaccination","volume":"374","author":"Peng","year":"2024","journal-title":"J Control Release"},{"key":"B32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.gendis.2019.12.004","article-title":"Immune checkpoint: the novel target for antitumor therapy","volume":"8","author":"Jiang","year":"2021","journal-title":"Genes Dis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"151875","DOI":"10.1016\/j.imbio.2019.11.010","article-title":"Promising approaches in cancer immunotherapy","volume":"225","author":"Taefehshokr","year":"2020","journal-title":"Immunobiology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-024-01581-2","article-title":"Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer","volume":"17","author":"Cheng","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2024.0055","article-title":"Immune checkpoint inhibitors: breakthroughs in cancer treatment","volume":"21","author":"Kong","year":"2024","journal-title":"Cancer Biol Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00345-8","article-title":"The foundations of immune checkpoint blockade and the ipilimumab approval decennial","volume":"21","author":"Korman","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B38","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.3390\/ijms25021274","article-title":"The Role of the CD28 Family Receptors in T\u2011Cell Immunomodulation","volume":"25","author":"Ciesielska\u2011Figlon","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-022-01325-0","article-title":"Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts","volume":"15","author":"Wang","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1198365","article-title":"Current understanding of CTLA-4: from mechanism to autoimmune diseases","volume":"14","author":"Hossen","year":"2023","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"101298","DOI":"10.1016\/j.smim.2019.101298","article-title":"CTLA-4 (CD152): a versatile receptor for immune-based therapy","volume":"42","author":"Lingel","year":"2019","journal-title":"Semin Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1571892","article-title":"PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations","volume":"15","author":"Jiang","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"B43","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00109-024-02463-3","article-title":"PD-1\/PD-L1 axis: implications in immune regulation, cancer progression, and translational applications","volume":"102","author":"Ortega","year":"2024","journal-title":"J Mol Med (Berl)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.4417077","article-title":"Efficacy and predictors of immune checkpoint inhibitors in patients with gallbladder cancer","volume":"115","author":"Cheng","year":"2024","journal-title":"Cancer Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.12.014","article-title":"Integrative proteogenomic analysis provides molecular insights and clinical significance in gallbladder cancer","volume":"44","author":"Fu","year":"2026","journal-title":"Cancer Cell"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000003883","article-title":"Single-cell profiling unveils the immuno-favorable tumor microenvironment remodeling after successful neoadjuvant therapy for advanced gallbladder cancer","volume":"112","author":"Tang","year":"2026","journal-title":"Int J Surg (London England)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1172\/jci193672","article-title":"Macrophage-rich niches regulate T cell dynamics at the liver invasive margin during gallbladder cancer progression","volume":"136","author":"Li","year":"2026","journal-title":"J Clin Invest"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216675","article-title":"Single-cell characterization of infiltrating T cells identifies novel targets for gallbladder cancer immunotherapy","volume":"586","author":"Zhang","year":"2024","journal-title":"Cancer Lett"},{"key":"B49","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s40164-024-00550-2","article-title":"M2-like tumor-associated macrophage-secreted CCL2 facilitates gallbladder cancer stemness and metastasis","volume":"13","author":"Chen","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.06.023","article-title":"Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer","volume":"75","author":"Zhang","year":"2021","journal-title":"J Hepatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-025-02236-9","article-title":"Multi-omic analysis of gallbladder cancer identifies distinct tumor microenvironments associated with disease progression","volume":"57","author":"Zhou","year":"2025","journal-title":"Nat Genet"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-331773","article-title":"Comprehensive single-cell analysis deciphered microenvironmental dynamics and immune regulator olfactomedin 4 in pathogenesis of gallbladder cancer","volume":"73","author":"He","year":"2024","journal-title":"Gut"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2026.218386","article-title":"ERR\u03b1-ETV5 axis drives PD-L1 upregulation and immune escape in gallbladder cancer","volume":"646","author":"Wang","year":"2026","journal-title":"Cancer Lett"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1452345","article-title":"Aspartate beta-hydroxylase is a prognostic factor in gallbladder cancer with the function of promoting tumorigenesis and chemoresistance","volume":"16","author":"Yuan","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1637300","article-title":"Extracellular matrix remodeling fibroblasts govern the tumor microenvironment disparity between adenomatous lesions and adenocarcinoma in gallbladder","volume":"16","author":"Ma","year":"2025","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13046-020-01812-7","article-title":"Thrombospondin 4\/integrin \u03b12\/HSF1 axis promotes proliferation and cancer stem-like traits of gallbladder cancer by enhancing reciprocal crosstalk between cancer-associated fibroblasts and tumor cells","volume":"40","author":"Shi","year":"2021","journal-title":"J Exp Clin Cancer Res CR"},{"key":"B57","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13062-025-00683-2","article-title":"Matrix stiffness induced gallbladder fibroblasts activation and paracrine SEMA7A promotes gallbladder cancer cell epithelial-mesenchymal transition and cancer stem cell-like properties by modulating AKT\/p300 signalling","volume":"20","author":"Sun","year":"2025","journal-title":"Biol Direct"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2025.216767","article-title":"Liquid biopsy for cancer immunotherapy: Biomarkers to predict and monitor response upon immune checkpoint blockade","volume":"539","author":"Son","year":"2025","journal-title":"Coord Chem Rev"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2026.116711","article-title":"From prediction to precision: Biomarker discovery and predictive modeling for personalized immune checkpoint blockade therapy","volume":"239","author":"Wijnen","year":"2026","journal-title":"Eur J Cancer (Oxford Engl 1990)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11112933","article-title":"Comparison of efficacy and safety of anti-programmed cell death-1 antibody plus lenvatinib and chemotherapy as first-line therapy for patients with stage IV gallbladder cancer: A real-world study in a Chinese population","volume":"11","author":"Wu","year":"2023","journal-title":"Biomedicines"},{"key":"B61","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s00262-024-03831-1","article-title":"Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer","volume":"73","author":"Tan","year":"2024","journal-title":"Cancer Immunology Immunotherapy CII"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1120009x.2025.2568807","article-title":"Integrating immunotherapy into chemotherapy: real-world efficacy of GEMOX plus tislelizumab in advanced gallbladder cancer","author":"Zhang","year":"2025","journal-title":"J Chemotherapy (Florence Italy)"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s346635","article-title":"Successful treatment of metastatic gallbladder carcinoma with PD-L1 expression by the combination of PD-1 inhibitor plus bevacizumab with chemotherapy: A case report","volume":"15","author":"Guo","year":"2022","journal-title":"OncoTargets Ther"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-0327","article-title":"FDA approval summary: Pembrolizumab for the treatment of tumor mutational burden-high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res Off J Am Assoc For Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010311","article-title":"Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types","volume":"13","author":"Gandara","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006454","article-title":"High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis","volume":"11","author":"Jung","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.7150\/thno.56539","article-title":"Mutational spectrum and precision oncology for biliary tract carcinoma","volume":"11","author":"Lin","year":"2021","journal-title":"Theranostics"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.1610-23","article-title":"Successful treatment of metastatic gallbladder carcinoma with a high tumor mutational burden using pembrolizumab","volume":"62","author":"Uehara","year":"2023","journal-title":"Internal Med (Tokyo Japan)"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1144371","article-title":"Case report: Preliminary response to tislelizumab plus S-1 in patients with metastatic gallbladder carcinoma: A report of five cases and a literature review","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.795972","article-title":"Neoadjuvant immunotherapy for MSI-H\/dMMR locally advanced colorectal cancer: New strategies and unveiled opportunities","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41571-025-01015-z","article-title":"Epidemiology, pathogenesis, biology and evolving management of MSI-H\/dMMR cancers","volume":"22","author":"Ambrosini","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13000-019-0813-5","article-title":"Low frequency of mismatch repair deficiency in gallbladder cancer","volume":"14","author":"Goeppert","year":"2019","journal-title":"Diagn Pathol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"5257","DOI":"10.1016\/j.hpb.2022.05.1021","article-title":"Gallbladder cancer: Current insights in genetic alterations and their possible therapeutic implications","volume":"13","author":"Kuipers","year":"2021","journal-title":"Cancers"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyab073","article-title":"A phase II study of pembrolizumab in combination with capecitabine and oxaliplatin with molecular profiling in patients with advanced biliary tract carcinoma","volume":"27","author":"Monge","year":"2022","journal-title":"Oncologist"},{"key":"B76","doi-asserted-by":"publisher","first-page":"S1170","DOI":"10.1016\/j.annonc.2020.08.2271","article-title":"LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours","volume":"31","author":"Lwin","year":"2020","journal-title":"Ann Oncol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"S146","DOI":"10.1016\/j.annonc.2021.05.194","article-title":"P-139 A phase 2 multicohort study (LEAP-005) of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors: Pancreatic cancer cohort","volume":"32","author":"Chung","year":"2021","journal-title":"Ann Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.2814","article-title":"Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: Subgroup analysis of a phase 2 nonrandomized clinical trial","volume":"6","author":"Klein","year":"2020","journal-title":"JAMA Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35243","article-title":"SWOG 1609 cohort 48: anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancer","volume":"130","author":"Patel","year":"2024","journal-title":"Cancer"},{"key":"B80","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1016\/j.annonc.2024.05.288","article-title":"282P Nivolumab and ipilimumab combination treatment in advanced intrahepatic cholangiocarcinoma and gallbladder cancer","volume":"35","author":"Klein","year":"2024","journal-title":"Ann Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0930","article-title":"A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer","volume":"6","author":"Kim","year":"2020","journal-title":"JAMA Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.4_suppl.570","article-title":"Adjuvant chemoradiation and immunotherapy for extrahepatic cholangiocarcinoma and gallbladder cancer: A randomized clinical trial","volume":"11","author":"Xiao","year":"2025","journal-title":"JAMA Oncol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"S1853","DOI":"10.1016\/j.annonc.2025.10.116","article-title":"289P Efficacy and safety of camrelizumab plus gemcitabine and oxaliplatin as conversion therapy for unresectable gallbladder cancer: Interim results from a single-arm, phase II prospective clinical study","volume":"36","author":"Deng","year":"2025","journal-title":"Ann Oncol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/s41392-025-02356-y","article-title":"First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study","volume":"10","author":"Shi","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(25)00376-6","article-title":"Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study","volume":"26","author":"Shi","year":"2025","journal-title":"Lancet Oncol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"5559","DOI":"10.1038\/s41467-025-60119-3","article-title":"Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trial","volume":"16","author":"Li","year":"2025","journal-title":"Nat Commun"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2022.100255","article-title":"Toripalimab in advanced biliary tract cancer","volume":"3","author":"Li","year":"2022","journal-title":"Innovation"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.751391","article-title":"Lenvatinib plus PD-1 inhibitors as first-line treatment in patients with unresectable biliary tract cancer: A single-arm, open-label, phase II study","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-24-463","article-title":"Phase II trial of hepatic arterial infusion chemotherapy plus bevacizumab and toripalimab for advanced biliary tract cancers: efficacy, safety, and exploratory analysis","volume":"15","author":"Zheng","year":"2026","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.05.003","article-title":"Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study","volume":"83","author":"Oh","year":"2025","journal-title":"J Hepatol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00082-2","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Burris","year":"2024","journal-title":"Lancet Oncol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/s2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/evidoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70428","article-title":"Durvalumab in advanced biliary tract cancer: Real-world data from a large cohort of patients across multiple international centers","volume":"45","author":"Rimini","year":"2025","journal-title":"Liver Int"},{"key":"B95","doi-asserted-by":"publisher","first-page":"114199","DOI":"10.1016\/j.annonc.2024.05.299","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population","volume":"208","author":"Rimini","year":"2024","journal-title":"Eur J Cancer"},{"key":"B96","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00262-024-03842-y","article-title":"Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical data","volume":"73","author":"Reimann","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-024-01060-1","article-title":"Durvalumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin in biliary tract cancer: a real-world retrospective, multicenter study","volume":"19","author":"Rimini","year":"2024","journal-title":"Target Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.04.097","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: an early exploratory analysis of real-world data","volume":"43","author":"Rimini","year":"2023","journal-title":"Liver Int"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.122","article-title":"86P outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study","volume":"33","author":"He","year":"2022","journal-title":"Ann OncologyAbstract Book ofthe ESMO Asia Congress 2022 2-4 December 2022"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1200\/jco.24.00337","article-title":"Atezolizumab plus chemotherapy with or without bevacizumab in advanced biliary tract cancer: clinical and biomarker data from the randomized phase II IMbrave151 trial","volume":"43","author":"Macarulla","year":"2025","journal-title":"J Clin Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000365","article-title":"Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced\/metastatic biliary tract cancers","volume":"78","author":"Yoo","year":"2023","journal-title":"Hepatology"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2022.09.004","article-title":"Immune checkpoint inhibitor therapy in oncology: current uses and future directions: JACC: CardioOncology state-of-the-art review","volume":"4","author":"Tan","year":"2022","journal-title":"JACC CardioOncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108277","article-title":"Development and validation of a reporter gene assay to determine the bioactivity of anti-CTLA-4 monoclonal antibodies","volume":"101","author":"Liu","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4593","article-title":"Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer","volume":"11","author":"Doki","year":"2022","journal-title":"Cancer Med"},{"key":"B105","doi-asserted-by":"publisher","first-page":"S563","DOI":"10.1016\/j.annonc.2022.07.080","article-title":"52MO a randomized phase II trial of durvalumab and tremelimumab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-na\u00efve patients with cholangio- and gallbladder carcinoma (IMMUCHEC)","volume":"33","author":"Vogel","year":"2022","journal-title":"Ann Oncol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0961","article-title":"ADJUBIL: phase II study of adjuvant immunotherapy with STRIDE regimen with\/without capecitabine in biliary tract cancers","volume":"20","author":"Goetze","year":"2024","journal-title":"Future Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6912","article-title":"Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma","volume":"13","author":"Monge","year":"2024","journal-title":"Cancer Med"},{"key":"B108","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ejca.2020.10.027","article-title":"Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial","volume":"143","author":"Boil\u00e8ve","year":"2021","journal-title":"Eur J Cancer"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2026.114650","article-title":"Next generation CAR-T cells to tackle solid tumors","volume":"391","author":"Abreu","year":"2026","journal-title":"J Controlled Release"},{"key":"B110","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.canlet.2021.01.014","article-title":"Tumor-tagging by oncolytic viruses: a novel strategy for CAR-T therapy against solid tumors","volume":"503","author":"Tang","year":"2021","journal-title":"Cancer Lett"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2023.2225291","article-title":"Preclinical evaluation of chimeric antigen receptor T cells targeting the carcinoembryonic antigen as a potential immunotherapy for gallbladder cancer","volume":"12","author":"Lopez","year":"2023","journal-title":"Oncoimmunology"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102349","article-title":"Therapeutic T cells with 3-in-1 strategy for the treatment of biliary tract cancer","volume":"6","author":"Wan","year":"2025","journal-title":"Cell Rep Med"},{"key":"B113","unstructured":"National Comprehensive Cancer Network\n          NCCN Clinical Practice Guidelines in Oncology: Biliary Tract Cancers, Version 1.2026\n          \n          2026"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0042","article-title":"Biliary tract cancers, version 2.2025, NCCN clinical practice guidelines in oncology","volume":"23","author":"Benson","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-24-352","article-title":"The evolving landscape of biliary tract cancers: comparing French and US National Comprehensive Cancer Network guidelines","volume":"13","author":"Ozer","year":"2024","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-24-63","article-title":"Insights on liver-directed surgical innovations, targeted therapies, and immunotherapy for biliary tract cancer: navigating the new European Society for Medical Oncology (ESMO) clinical practice guidelines","volume":"13","author":"Maker","year":"2024","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104003","article-title":"ESMO clinical practice guideline interim update on the management of biliary tract cancer","volume":"10","author":"Vogel","year":"2025","journal-title":"ESMO Open"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101170","article-title":"New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe","volume":"50","author":"Rimassa","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103647","article-title":"Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer","volume":"9","author":"Chen","year":"2024","journal-title":"ESMO Open"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000003258","article-title":"Chinese national clinical practice guideline on diagnosis and treatment of biliary tract cancers","volume":"137","author":"Wang","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112139-20240203-00062","article-title":"Chinese expert consensus on the whole-course standardized management of biliary tract cancer (2023)","volume":"62","year":"2024","journal-title":"Zhonghua Wai Ke Za Zhi"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112139-20250310-00118","article-title":"Expert consensus on conversion therapy of biliary tract cancer (2025)","volume":"63","year":"2025","journal-title":"Zhonghua Wai Ke Za Zhi"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114000","article-title":"Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT)","volume":"202","author":"Roth","year":"2024","journal-title":"Eur J Cancer"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-025-03916-y","article-title":"SEOM-GEMCAD-TTD clinical guidelines for biliary tract cancer (2025)","volume":"27","author":"Macarulla","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30080517","article-title":"A practical guide for the systemic treatment of biliary tract cancer in Canada","volume":"30","author":"Ramjeesingh","year":"2023","journal-title":"Curr Oncol"},{"key":"B127","unstructured":"KEYTRUDA (Pembrolizumab) Prescribing Information\n          \n          2025"},{"key":"B128","unstructured":"IMFINZI (Durvalumab) Prescribing Information\n          \n          2025"},{"key":"B129","unstructured":"KEYTRUDA (Pembrolizumab) Prescribing Information (Chinese Version)\n          \n          2024"},{"key":"B130","unstructured":"IMFINZI (Durvalumab for Injection) Package Insert (Chinese Version)\n          \n          2023"},{"key":"B131","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41577-021-00617-9","article-title":"Checkpoint blockade: the end of the beginning","volume":"21","author":"Wolchok","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.clsc.2017.09.001","article-title":"Cutting the brakes: immunotherapy with PD-1 inhibitors","volume":"2","author":"Sweis","year":"2017","journal-title":"Clin Skin Cancer"},{"key":"B133","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13045-025-01734-x","article-title":"Immune checkpoint inhibitors for the treatment of solid tumors and lymphoma in the past 26 years (2000-2025)","volume":"18","author":"Huang","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10238-024-01546-2","article-title":"Beyond checkpoint inhibitors: the three generations of immunotherapy","volume":"25","author":"Schaub","year":"2025","journal-title":"Clin Exp Med"},{"key":"B135","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s10238-024-01404-1","article-title":"Current status and progress of PD-L1 detection: guiding immunotherapy for non-small cell lung cancer","volume":"24","author":"Qi","year":"2024","journal-title":"Clin Exp Med"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4143\/crt.2025.1161","article-title":"Diagnostic challenges and clinical implications of microsatellite instability\/mismatch repair deficiency in solid tumors","volume":"58","author":"Kwak","year":"2026","journal-title":"Cancer Res Treat"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1186\/s13053-025-00308-9","article-title":"Tumour mutational burden using a targeted panel approach for comprehensive tumour profiling focusing on colorectal cancer","volume":"23","author":"Scott","year":"2025","journal-title":"Hered Cancer Clin Pract"},{"key":"B138","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s12672-026-04436-z","article-title":"Bibliometric analysis of research trends and hotspots in immunotherapy biomarkers for non-small cell lung cancer from 2015 to 2024","volume":"17","author":"Meng","year":"2026","journal-title":"Discov Oncol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.2196\/32728","article-title":"Research trends in immune checkpoint blockade for melanoma: visualization and bibliometric analysis","volume":"24","author":"Xu","year":"2022","journal-title":"J Med Internet Res"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000041739","article-title":"Therapeutic potential of triple-negative breast cancer immune checkpoint blockers: a 21-year bibliometric analysis","volume":"104","author":"Sun","year":"2025","journal-title":"Med (Baltimore)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1862775\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T11:33:33Z","timestamp":1786016013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1862775\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":140,"alternative-id":["10.3389\/fimmu.2026.1862775"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1862775","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"article-number":"1862775"}}